Aurora Spine (ASG) investor relations material

Company overview and market positioning

• Commercialized a screwless lumbar fusion device, ZIP, enabling minimally invasive outpatient procedures.

• Focus shifted from Europe to North America, with primary sales in the U.S.

• Expanded from orthopedic/neuro spine to interventional spine markets, training doctors in new procedures.

• Emphasizes simplifying complex procedures to broaden patient access and expand the product portfolio.

Product development and launches

• Finalized and launched Apollo cervical plate and DEXA cervical cage, offering a comprehensive cervical solution.

• DEXA-L, a bone-matched lumbar implant, launched in 2025, with strong clinical outcomes and further expansion planned.

• New biologics portfolio (OsteoGraft, TurboFuse, OsteoSponge) launched, integrated with implants for a one-stop solution.

• SiLO SI joint fusion system expanded to include multiple approaches, with DEXA technology integration planned for 2026.

Sales strategy and growth initiatives

• Building a national direct sales team, with regional directors and territory managers to be added in 2026.

• Tripling or quadrupling product sets in key areas to increase market reach and revenue.

• Introducing disposable instrument kits in 2026 to improve efficiency and market penetration.